Direct human evidence for the material commonly sold as modified GRF(1-29) or “CJC without DAC” is very limited. Some related growth-hormone-releasing molecules have human data, but that cannot be treated as proof for this exact product.
Still uncertain: Direct information on how the body handles it, dose-response, human benefit, long-term safety, body-composition benefit or equivalence of marketplace products.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
No dedicated peer-reviewed human clinical trial of the exact tetrasubstituted Modified GRF(1-29) / 'CJC-1295 without DAC' product was identified in this search. Related human studies of native GHRH(1-29), D-Ala2 analogues and CJC-1295 with DAC establish GHRH biology but are different molecules.
Regulatory status
No specific FDA-approved product named 'CJC-1295 without DAC' was identified.
Main limitations
Direct human PK, dose-response, efficacy, long-term safety, body-composition benefit or equivalence of marketplace products.
Safety
Endocrine adverse effects and product-identity uncertainty; long-term non-indicated use is not established.
Evidence reviewed
2026-09-18
i
No dedicated peer-reviewed human clinical trial of the exact tetrasubstituted Modified GRF(1-29) / 'CJC-1295 without DAC' product was identified in this search. Related human studies of native GHRH(1-29), D-Ala2 analogues and CJC-1295 with DAC establish GHRH biology but are different molecules.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Endocrine adverse effects and product-identity uncertainty; long-term non-indicated use is not established.
Compound-specific human safety is not established. Related GHRH analogues can cause transient flushing and raise GH/IGF-I, but those data cannot define Mod GRF risk.
Route / formulation boundaryChemical identity should be confirmed because 'without DAC' is often used loosely for modified GRF(1-29).
Identity / data-quality noteDo not merge Modified GRF(1-29) with CJC-1295-DAC or native sermorelin. The literature belongs to distinct molecules.
Study / label regimen evidenceStudy-regimen evidence reviewed. Human dosing exists for native GHRH(1-29)/sermorelin, but it should not be transferred to an unverified Modified GRF(1-29)/'CJC without DAC' product identity.
Identifiers & alternate namesCJC without DAC · CJC no DAC · Mod GRF 1-29 · CJC w/out DAC
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
2outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
PubMed / peer-reviewed source ↗ — Supports contraindication, interaction, monitoring, pregnancy or formulation-safety context in the safety evidence layer.
PubMed / peer-reviewed source ↗ — Supports contraindication, interaction, monitoring, pregnancy or formulation-safety context in the safety evidence layer.
PubMed / peer-reviewed source ↗ — Reviews GH-IGF-1-axis compounds including marketplace 'CJC-1295 without DAC' and highlights gaps between clinical evidence and self-administration.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
